Oxford, UK – 1 May 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford BioMedica’s LentiVector… Read More
— First patient treated at Velindre Cancer Centre, Wales (UK) — Oxford, UK – 7 March 2013: Oxford BioMedica plc (“Oxford BioMedica” or… Read More
Click here to download the full 2012 preliminary results statement.Click here to download the 2012 results slide deck.Click here to listen to the… Read More
Oxford, UK – 23 January 2013: Oxford BioMedica plc (LSE:OXB), the leading gene-based biopharmaceutical company, will be announcing its preliminary results for the twelve months ended 31 December 2012 on Wednesday, 27 February 2013. Read More
— ImaginAb acquires exclusive worldwide licence for 5T4-based imaging diagnostic — Oxford, UK and Los Angeles, CA – 29 November 2012: Oxford BioMedica (“Oxford… Read More
— Positive DSMB review of first patient cohort in UshStat® Phase I/IIa Study —— Further encouraging data from RetinoStat® and StarGen™ clinical studies —… Read More
Oxford, UK 14 November 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 July to 13 November 2012. Read More
– Leading intellectual property position further strengthened — Oxford, UK – 9 November 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the… Read More
Oxford, UK – 10 October 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it plans to close the Phase II study in the United States (US) to assess the activity… Read More
— Appointment of New Non-Executive Director — Oxford, UK – 3 October 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading… Read More
Oxford, UK and Seattle, WA, USA – 27 September 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, has signed a master services agreement with Immune Design Corp. (Immune Design), a… Read More
Click here to download the full 2012 interim results statement.Click here to download the 2012 interim results presentation.Click here to listen to the audio replay… Read More